MAPS Announces Agreement with UAB
MAPS can now share we have finalized a clinical trial agreement with the University of Alabama, Birmingham, making UAB the first official site for the MJP2 study of inhaled cannabis in the treatment of …
Medical Marijuana Research News
Clinical-Trial Cannabis and Placebo has Been Shipped
Following the issuance of an import permit by Health Canada in June 2026, Research Triangle Institute, the contracted licensed distributor for the National Institute on Drug Abuse (NIDA) Drug Supply Program, …
MAPS Receives Approval for Placebo Cannabis
On March 13th 2026 MAPS received notice that the NIDA Drug Supply Program (NDSP) – which provides qualified researchers with free or low-cost controlled substances, research chemicals, and cannabis products …
MAPS Submits Protocol Amendment 4, Version 1 to FDA for MJP2 Phase 2 Study
On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. …
MAPS Submits 2025 Cannabis Data Safety Update Report to FDA for MJP2 Phase 2 Study
On January 13, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted the 2025 Cannabis Data Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). The …
MAPS Partners with Changemark to Advance Cannabis PTSD Research for Veterans
August 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization …
MAPS Submits Cannabis Data Safety Update Report 2024 and Protocol Amendment to FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)
On January 15, 2025, MAPS submitted to the FDA the 2024 Cannabis Data Safety Update Report (DSUR) along with a protocol amendment. The DSUR serves as the FDA Annual Report on the progress of the drug …
FDA authorizes clinical trials to study cannabis use for veterans with PTSD | Stars and Stripes
FDA gives green light to PTSD marijuana study in veterans | The Hill
FDA Approves Long-Awaited Clinical Trial Of Smoked Marijuana To Treat PTSD In Veterans | Marijuana Moment
Weed for PTSD? Eager for Better Cannabis Science, F.D.A. Clears Study. | The New York Times
MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute
FOR IMMEDIATE RELEASE: November 20, 2024 The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the Multidisciplinary Association for Psychedelic Studies (MAPS)’ Phase …